News

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform.

Poster Presentations to highlight the latest research on OBI-992 (anti-TROP2 …

OBI Pharma to present the Study Results of OBI-992 at the 14th World ADC London

OBI Pharma is excited to announce that Dr. Ming-Tain Lai, …

OBI announces the termination of OBI-3424 Phase II trial

Following a strategic portfolio review, the Board of Directors of …

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992

First clinical trial to evaluate the safety and efficacy of …

Kung-Yee Liang, PH.D. was elected as the chairman of OBI Pharma, Inc.

OBI Pharma, Inc. (4174.TWO) held a board meeting today (29th) …

OBI Pharma proprietary ADC technology platform “plug and play”

site-specific conjugation, scalable manufacturing process, and suitability for various antibodies, …

OBI Achieves ISO/IEC 27001 International Information Security Certification

After two years of continuous effort, OBI has successfully established …

OBI VOLUNTEERS ON A MISSION!

▲ OBI Volunteers Team.  Photo / Provided by TBCA In …

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. appointed as Chief Executive Officer

Dr. Wang appointed by the OBI Pharma Board of Directors …

Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

Title: OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic …